tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Penumbra Appoints Shruthi Narayan as New President

Story Highlights
  • Penumbra appointed Shruthi Narayan as President, effective September 1, 2025.
  • Her leadership is expected to sustain Penumbra’s growth and expand access to its technology.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Penumbra Appoints Shruthi Narayan as New President

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Penumbra ( (PEN) ) has provided an update.

On August 22, 2025, Penumbra, Inc. appointed Shruthi Narayan as President, effective September 1, 2025. Ms. Narayan, who joined Penumbra in 2013, has been instrumental in building the company’s peripheral vascular division and commercializing its vascular portfolio globally. Her appointment is expected to sustain Penumbra’s growth and market leadership in the medical device industry, particularly in thrombectomy technologies. Adam Elsesser will continue as Chairman and CEO, while Ms. Narayan’s leadership is anticipated to expand access to Penumbra’s life-saving technology worldwide.

The most recent analyst rating on (PEN) stock is a Buy with a $295.00 price target. To see the full list of analyst forecasts on Penumbra stock, see the PEN Stock Forecast page.

Spark’s Take on PEN Stock

According to Spark, TipRanks’ AI Analyst, PEN is a Outperform.

Penumbra’s overall stock score is driven by its strong financial performance and positive technical indicators, despite a high valuation. The company’s robust revenue growth and efficient cash management are significant strengths. However, the high P/E ratio suggests potential overvaluation, and technical indicators hint at overbought conditions, which could limit upside potential.

To see Spark’s full report on PEN stock, click here.

More about Penumbra

Penumbra, Inc., the world’s leading thrombectomy company, focuses on developing innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism, and acute limb ischemia. Their broad portfolio includes computer-assisted vacuum thrombectomy (CAVT), aiming to remove blood clots efficiently and safely. Penumbra supports healthcare providers in over 100 countries, enhancing patient outcomes and quality of life.

Average Trading Volume: 466,937

Technical Sentiment Signal: Strong Buy

Current Market Cap: $10.37B

For an in-depth examination of PEN stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1